CD73 plays a protective role in collagen-induced arthritis

Journal of Immunology

Volumn 194, Issue 6, 2015, Pages 2487-2492

  Chrobak, Pavel ^a   Charlebois, Roxanne ^a   Rejtar, Pavel ^b   El Bikai, Rana ^a   Allard, Bertrand ^a   Stagg, John ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 5' NUCLEOTIDASE; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR AGONIST; COLLAGEN ANTIBODY; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; PLACEBO; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; 2-(4-(2-CARBOXYETHYL)PHENETHYLAMINO)-5'-N-ETHYLCARBOXAMIDOADENOSINE; ADENOSINE; ADENOSINE A2 RECEPTOR AGONIST; AUTACOID; AVIAN PROTEIN; COLLAGEN TYPE 2; CYTOKINE; IMMUNOGLOBULIN G; PHENETHYLAMINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CD73 GENE; CELLULAR IMMUNITY; CHIMERA; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG SELECTIVITY; DRUG TARGETING; GENE CONTROL; GENE DELETION; GENETIC SUSCEPTIBILITY; INFLAMMATION; JOINT DESTRUCTION; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RECEPTOR UPREGULATION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; TH1 CELL; WILD TYPE; ANALOGS AND DERIVATIVES; ANIMAL; ARTHRITIS, EXPERIMENTAL; BONE MARROW TRANSPLANTATION; C57BL MOUSE; CD4+ T LYMPHOCYTE; CHICKEN; DEFICIENCY; DISEASE PREDISPOSITION; DISEASE RESISTANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; IMMUNOLOGY; JOINT; LYMPH NODE; METABOLISM; PATHOLOGY;

5'-NUCLEOTIDASE; ADENOSINE; ADENOSINE A2 RECEPTOR AGONISTS; ANIMALS; ARTHRITIS, EXPERIMENTAL; AVIAN PROTEINS; BONE MARROW TRANSPLANTATION; CD4-POSITIVE T-LYMPHOCYTES; CHICKENS; COLLAGEN TYPE II; CYTOKINES; DISEASE RESISTANCE; DISEASE SUSCEPTIBILITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNOGLOBULIN G; INFLAMMATION MEDIATORS; INTERFERON-GAMMA; JOINTS; LYMPH NODES; MICE, INBRED C57BL; MICE, KNOCKOUT; PHENETHYLAMINES; TH1 CELLS;

EID: 84924631508     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1401416     Document Type: Article

References (20)

1. Brand, D. D., K. A. Latham, and E. F. Rosloniec. 2007. Collagen-induced arthritis. Nat. Protoc. 2: 1269-1275.
2. Silverman, M. H., V. Strand, D. Markovits, M. Nahir, T. Reitblat, Y. Molad, I. Rosner, M. Rozenbaum, R. Mader, M. Adawi, et al. 2008. Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial. J. Rheumatol. 35: 41-48.
3. Allard, B., M. Turcotte, and J. Stagg. 2012. CD73-generated adenosine: orchestrating the tumor-stroma interplay to promote cancer growth. J. Biomed. Biotechnol. 2012: 485156.
4. Blume, C., A. Felix, N. Shushakova, F. Gueler, C. S. Falk, H. Haller, and J. Schrader. 2012. Autoimmunity in CD73/ecto-59-nucleotidase deficient mice induces renal injury. PLoS One 7: e37100.
5. Mills, J. H., L. F. Thompson, C. Mueller, A. T. Waickman, S. Jalkanen, J. Niemela, L. Airas, and M. S. Bynoe. 2008. CD73 is required for efficient entry of lymphocytes into the central nervous system during experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA 105: 9325-9330.
6. Johnson, S. M., S. Patel, F. E. Bruckner, and D. A. Collins. 1999. 59-Nucleotidase as a marker of both general and local inflammation in rheumatoid arthritis patients. Rheumatology (Oxford) 38: 391-396.
7. Botta Gordon-Smith, S., S. Ursu, S. Eaton, H. Moncrieffe, and L. R. Wedderburn. 2015. Correlation of low CD73 expression on synovial lymphocytes with reduced adenosine generation and higher disease severity in juvenile idiopathic arthritis. Arthritis Rheum. 67: 545-554.
8. Moncrieffe, H., K. Nistala, Y. Kamhieh, J. Evans, A. Eddaoudi, S. Eaton, and L. R. Wedderburn. 2010. High expression of the ectonucleotidase CD39 on T cells from the inflamed site identifies two distinct populations, one regulatory and one memory T cell population. J. Immunol. 185: 134-143.
9. Seeuws, S., P. Jacques, J. Van Praet, M. Drennan, J. Coudenys, T. Decruy, E. Deschepper, L. Lepescheux, P. Pujuguet, L. Oste, et al. 2010. A multiparameter approach to monitor disease activity in collagen-induced arthritis. Arthritis Res. Ther. 12: R160.
10. Chang, C. B., S. A. Han, E. M. Kim, S. Lee, S. C. Seong, and M. C. Lee. 2013. Chondrogenic potentials of human synovium-derived cells sorted by specific surface markers. Osteoarthritis and cartilage/OARS. Osteoarthritis Research Society 21: 190-199.
11. Flögel, U., S. Burghoff, P. L. van Lent, S. Temme, L. Galbarz, Z. Ding, A. El-Tayeb, S. Huels, F. Bönner, N. Borg, et al. 2012. Selective activation of adenosine A2A receptors on immune cells by a CD73-dependent prodrug suppresses joint inflammation in experimental rheumatoid arthritis. Sci. Transl. Med. 4: ra108.
12. Morabito, L., M. C. Montesinos, D. M. Schreibman, L. Balter, L. F. Thompson, R. Resta, G. Carlin, M. A. Huie, and B. N. Cronstein. 1998. Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-59-nucleotidase-mediated conversion of adenine nucleotides. J. Clin. Invest. 101: 295-300.
13. Mazzon, E., E. Esposito, D. Impellizzeri, R. DI Paola, A. Melani, P. Bramanti, F. Pedata, and S. Cuzzocrea. 2011. CGS 21680, an agonist of the adenosine (A2A) receptor, reduces progression of murine type II collagen-induced arthritis. J. Rheumatol. 38: 2119-2129.
14. Baharav, E., S. Bar-Yehuda, L. Madi, D. Silberman, L. Rath-Wolfson, M. Halpren, A. Ochaion, A. Weinberger, and P. Fishman. 2005. Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models. J. Rheumatol. 32: 469-476.
15. Varani, K., M. Padovan, F. Vincenzi, M. Targa, F. Trotta, M. Govoni, and P. A. Borea. 2011. A2A and A3 adenosine receptor expression in rheumatoid arthritis: upregulation, inverse correlation with disease activity score and suppression of inflammatory cytokine and metalloproteinase release. Arthritis Res. Ther. 13: R197.
16. Friedman, D. J., B. M. Künzli, Y. I. A-Rahim, J. Sevigny, P. O. Berberat, K. Enjyoji, E. Csizmadia, H. Friess, and S. C. Robson. 2009. From the cover: CD39 deletion exacerbates experimental murine colitis and human polymorphisms increase susceptibility to inflammatory bowel disease. Proc. Natl. Acad. Sci. USA 106: 16788-16793.
17. Schena, F., S. Volpi, C. E. Faliti, F. Penco, S. Santi, M. Proietti, U. Schenk, G. Damonte, A. Salis, M. Bellotti, et al. 2013. Dependence of immunoglobulin class switch recombination in B cells on vesicular release of ATP and CD73 ectonucleotidase activity. Cell Reports 3: 1824-1831.
18. Stagg, J., U. Divisekera, H. Duret, T. Sparwasser, M. W. Teng, P. K. Darcy, and M. J. Smyth. 2011. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res. 71: 2892-2900.
19. Kiss, J., G. G. Yegutkin, K. Koskinen, T. Savunen, S. Jalkanen, and M. Salmi. 2007. IFN-beta protects from vascular leakage via up-regulation of CD73. Eur. J. Immunol. 37: 3334-3338.
20. Lee, Y. H., S. C. Bae, and G. G. Song. 2014. Coffee or tea consumption and the risk of rheumatoid arthritis: a meta-analysis. Clin. Rheumatol. 33: 1575-1583.